WEBULL

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders

Simply Wall St · 1d ago
  • Teva Pharmaceutical Industries recently reported encouraging Phase 1b data for its investigational anti‑IL‑15 antibody TEV‑408 in non‑segmental vitiligo, showing improved skin repigmentation with no new safety issues and confirming plans to move into a Phase 2b trial supported by up to US$500.00 million in external R&D funding.
  • The quarterly subcutaneous dosing schedule and dual development in vitiligo and celiac disease position TEV‑408 as a potentially differentiated asset within Teva’s immunology pipeline and broader shift toward higher‑value innovative therapies.
  • Next, we’ll examine how TEV‑408’s quarterly dosing profile and encouraging early vitiligo data could reshape Teva’s innovation‑focused investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe its pivot from a mature generics base to higher value innovative and biosimilar therapies can support steady earnings growth while debt gradually comes down. The TEV‑408 vitiligo update strengthens Teva’s immunology story but is unlikely to change the key near term catalyst, which remains execution on the AUSTEDO, AJOVY and UZEDY franchises, or the biggest risk, its sizeable net debt burden.

The TEV‑408 news sits alongside Teva’s broader pipeline progress, including the recent NDA filing for ecopipam in pediatric Tourette syndrome, which, if approved, would further reinforce the company’s transition toward branded neuroscience and immunology assets that investors are watching as the next wave of potential growth drivers.

Yet against this progress, investors should still weigh the risk that pipeline setbacks or slower than expected uptake of new launches could...

Read the full narrative on Teva Pharmaceutical Industries (it's free!)

Teva Pharmaceutical Industries' narrative projects $18.1 billion revenue and $2.7 billion earnings by 2029.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $40.90 fair value, a 27% upside to its current price.

Exploring Other Perspectives

TEVA 1-Year Stock Price Chart
TEVA 1-Year Stock Price Chart

The most bearish analysts once assumed Teva’s revenue would grow only about 1 percent annually to US$17.3 billion with earnings near US$1.6 billion, so TEV‑408’s progress may challenge that cautious view and shows how sharply your assumptions about late stage assets can shift the story.

Explore 4 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth just $40.90!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

  • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
  • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.